TOT BIOPHARM International Company Limited

HKEX:1875.HK

2 (HKD) • At close September 20, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) HKD.

2023 Q42023 Q22022 Q42022 Q22021 Q42021 Q22020 Q42020 Q22019 Q42019 Q22018 Q42018 Q22018 Q12017 Q42017 Q22017 Q12016 Q4
Revenue 452.566328.063260.159182.01953.19323.1329.46113.0320.70224.60611.3279.8059.8059.80512.90212.90212.902
Cost of Revenue 128.58378.0648.08523.47839.7089.1433.823.1413.9647.3522.8291.4951.4951.4951.0611.0611.061
Gross Profit 323.983250.003212.074158.54113.48513.9895.6419.88916.73817.2548.4988.318.318.3111.84211.84211.842
Gross Profit Ratio 0.7160.7620.8150.8710.2540.6050.5960.7590.8090.7010.750.8480.8480.8480.9180.9180.918
Reseach & Development Expenses 53.92149.96980.970.268125.9588.749135.87199.325115.27475.80447.7747.16347.16347.16326.48426.48426.484
General & Administrative Expenses 37.20631.10436.88925.69829.51326.82322.73724.11860.03635.05523.7737.8027.8027.8022.2932.2932.293
Selling & Marketing Expenses 243.643197.376133.86370.09111.64711.20212.22713.72614.69616.8487.8869.7349.7349.7347.2227.2227.222
SG&A 280.531228.48171.34995.78941.1638.02534.96437.84474.73251.90331.65917.53617.53617.5369.5159.5159.515
Other Expenses 000000000-79.137-79.137-64.664-64.664-64.6642.4312.4312.431
Operating Expenses 345.359264.182245.062171.262157.757129.434165.95138.252198.556134.1250.2920.0350.0350.03538.42938.42938.429
Operating Income -6.463-14.576-31.983-6.948-140.012-115.445-163.064-128.363-160.52-110.977-67.874-59.152-59.152-59.152-26.588-26.588-26.588
Operating Income Ratio -0.014-0.044-0.123-0.038-2.632-4.991-17.235-9.851-7.754-4.51-5.992-6.033-6.033-6.033-2.061-2.061-2.061
Total Other Income Expenses Net -16.131-0.586-2.339-8.776-6.1990.443.749-0.82-23.094-4.709-6.951-7.914-7.914-7.914-10.584-10.584-10.584
Income Before Tax -22.594-15.162-34.322-15.724-146.211-115.005-159.315-129.183-183.614-115.686-74.825-67.066-67.066-67.066-37.172-37.172-37.172
Income Before Tax Ratio -0.05-0.046-0.132-0.086-2.749-4.972-16.839-9.914-8.869-4.702-6.606-6.84-6.84-6.84-2.881-2.881-2.881
Income Tax Expense 00.0010.819000000-6.378-6.378-7.313-7.313-7.313-10.515-10.515-10.515
Net Income -22.594-15.163-34.192-15.724-146.211-115.005-159.315-129.183-183.614-115.686-74.825-67.066-67.066-67.066-37.172-37.172-37.172
Net Income Ratio -0.05-0.046-0.131-0.086-2.749-4.972-16.839-9.914-8.869-4.702-6.606-6.84-6.84-6.84-2.881-2.881-2.881
EPS -0.031-0.021-0.049-0.027-0.25-0.2-0.28-0.23-0.49-0.39-0.22-0.12-0.12-0.12-0.065-0.065-0.065
EPS Diluted -0.031-0.021-0.049-0.027-0.25-0.2-0.28-0.23-0.49-0.39-0.22-0.12-0.12-0.12-0.065-0.065-0.065
EBITDA 15.7522.007-14.49210.064-123.688-100.516-148.412-114.101-148.204-99.136-67.415-62.551-62.551-62.551-33.729-33.729-33.729
EBITDA Ratio 0.0350.006-0.0560.055-2.325-4.345-15.687-8.757-7.159-4.029-5.952-6.38-6.38-6.38-2.614-2.614-2.614